Skip to main content

Table 1 Distribution of patient and tumor characteristics by body mass index (BMI) group

From: The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial

  

Total (n = 3754)

BMI (kg/m2)

p valuea

  

<25.0

25.0–29.9

30.0–34.9

35.0–39.9

≥40.0

  

Underweight/normal weight

Overweight

Slightly obese

Moderately obese

Severely obese

  

(n = 1758)

(n = 1208)

(n = 554)

(n = 177)

(n = 57)

Age (years)

Median

53.0

50.0

56.0

58.0

58.0

54.0

<0.001b

Range

21–86

21–86

22–79

32–77

33–74

29–74

Menopausal status

Premenopausal

1565 (41.7 %)

932 (53.0 %)

410 (33.9 %)

153 (27.6 %)

52 (29.4 %)

18 (31.6 %)

<0.001c

Postmenopausal

2189 (58.3 %)

826 (47.0 %)

798 (66.1 %)

401 (72.4 %)

125 (70.6 %)

39 (68.4 %)

Tumor size

pT1

1552 (41.3 %)

866 (49.3 %)

455 (37.7 %)

161 (29.1 %)

56 (31.6 %)

14 (24.6 %)

<0.001d

pT2

1929 (51.4 %)

785 (44.7 %)

666 (55.1 %)

342 (61.7 %)

101 (57.1 %)

35 (61.4 %)

pT3

198 (5.3 %)

73 (4.2 %)

70 (5.8 %)

35 (6.3 %)

14 (7.9 %)

6 (10.5 %)

pT4

52 (1.4 %)

18 (1.0 %)

13 (1.1 %)

13 (2.3 %)

6 (3.4 %)

2 (3.5 %)

Unknown

23 (0.6 %)

16 (0.9 %)

4 (0.3 %)

3 (0.5 %)

0 (0.0 %)

0 (0.0 %)

Nodal stage

pN0

1273 (33.9 %)

660 (37.5 %)

370 (30.6 %)

153 (27.6 %)

67 (37.9 %)

23 (40.4 %)

<0.001d

pN1

1705 (45.4 %)

789 (44.9 %)

564 (46.7 %)

265 (47.8 %)

68 (38.4 %)

19 (33.3 %)

pN2

511 (13.6 %)

212 (12.1 %)

174 (14.4 %)

94 (17.0 %)

24 (13.6 %)

7 (12.3 %)

pN3

236 (6.3 %)

76 (4.3 %)

94 (7.8 %)

40 (7.2 %)

18 (10.2 %)

8 (14.0 %)

Unknown

29 (0.8 %)

21 (1.2 %)

6 (0.5 %)

2 (0.4 %)

0 (0.0 %)

0 (0.0 %)

Histological grading

G1

176 (4.7 %)

81 (4.6 %)

59 (4.9 %)

27 (4.9 %)

8 (4.5 %)

1 (1.8 %)

0.126d

G2

1783 (47.5 %)

848 (48.2 %)

576 (47.7 %)

255 (46.0 %)

82 (46.3 %)

22 (38.6 %)

G3

1773 (47.2 %)

814 (46.3 %)

568 (47.0 %)

270 (48.7 %)

87 (49.2 %)

34 (59.6 %)

Unknown

22 (0.6 %)

15 (0.9 %)

5 (0.4 %)

2 (0.4 %)

0 (0.0 %)

0 (0.0 %)

Histological type

Invasive ductal

3060 (81.5 %)

1434 (81.6 %)

992 (82.1 %)

435 (78.5 %)

148 (83.6 %)

51 (89.5 %)

0.337c

Invasive lobular

419 (11.2 %)

188 (10.7 %)

138 (11.4 %)

72 (13.0 %)

19 (10.7 %)

2 (3.5 %)

Other

253 (6.7 %)

121 (6.9 %)

73 (6.0 %)

45 (8.1 %)

10 (5.6 %)

4 (7.0 %)

Unknown

22 (0.6 %)

15 (0.9 %)

5 (0.4 %)

2 (0.4 %)

0 (0.0 %)

0 (0.0 %)

Hormone receptor status

Negative

1100 (29.3 %)

531 (30.2 %)

337 (27.9 %)

163 (29.4 %)

44 (24.9 %)

25 (43.9 %)

0.049c

Positive

2633 (70.1 %)

1212 (68.9 %)

866 (71.7 %)

390 (70.4 %)

133 (75.1 %)

32 (56.1 %)

Unknown

21 (0.6 %)

15 (0.9 %)

5 (0.4 %)

1 (0.2 %)

0 (0.0 %)

0 (0.0 %)

HER2 status

Negative

2787 (74.2 %)

1304 (74.2 %)

887 (73.4 %)

417 (75.3 %)

135 (76.3 %)

44 (77.2 %)

0.838c

Positive

883 (23.5 %)

418 (23.8 %)

292 (24.2 %)

122 (22.0 %)

39 (22.0 %)

12 (21.1 %)

Unknown

84 (2.2 %)

36 (2.0 %)

29 (2.4 %)

15 (2.7 %)

3 (1.7 %)

1 (1.8 %)

Molecular subtype

Luminal A like

1426 (38.0 %)

673 (38.3 %)

454 (37.6 %)

222 (40.1 %)

63 (35.6 %)

14 (24.6 %)

0.050c

Luminal B like

619 (16.5 %)

262 (14.9 %)

214 (17.7 %)

93 (16.8 %)

39 (22.0 %)

11 (19.3 %)

HER2 positive

883 (23.5 %)

418 (23.8 %)

292 (24.2 %)

122 (22.0 %)

39 (22.0 %)

12 (21.1 %)

Triple negative

742 (19.8 %)

369 (21.0 %)

219 (18.1 %)

102 (18.4 %)

33 (18.6 %)

19 (33.3 %)

Unknown

84 (2.2 %)

36 (2.0 %)

29 (2.4 %)

15 (2.7 %)

3 (1.7 %)

1 (1.8 %)

Type of surgery

Breast conserving

2638 (70.3 %)

1205 (68.5 %)

859 (71.1 %)

399 (72.0 %)

135 (76.3 %)

40 (70.2 %)

0.229c

Mastectomy

1097 (29.2 %)

539 (30.7 %)

345 (28.6 %)

154 (27.8 %)

42 (23.7 %)

17 (29.8 %)

Unknown

19 (0.5 %)

14 (0.8 %)

4 (0.3 %)

1 (0.2 %)

0 (0.0 %)

0 (0.0 %)

Chemotherapy

FEC-DocG

1856 (49.4 %)

865 (49.2 %)

614 (50.8 %)

261 (47.1 %)

85 (48.0 %)

31 (54.4 %)

0.580c

FEC-Doc

1898 (50.6 %)

893 (50.8 %)

594 (49.2 %)

293 (52.9 %)

92 (52.0 %)

26 (45.6 %)

Undertreatment

Yes (<6 cycles CT)

359 (9.6 %)

149 (8.5 %)

113 (9.4 %)

64 (11.6 %)

24 (13.6 %)

9 (15.8 %)

0.029c

No (6 cycles CT)

3395 (90.4 %)

1609 (91.5 %)

1095 (90.6 %)

490 (88.4 %)

153 (86.4 %)

48 (84.2 %)

Antihormone therapy

No

1048 (27.9 %)

500 (28.4 %)

331 (27.4 %)

149 (26.9 %)

43 (24.3 %)

25 (43.9 %)

0.061c

Yes

2677 (71.3 %)

1242 (70.6 %)

868 (71.9 %)

401 (72.4 %)

134 (75.7 %)

32 (56.1 %)

Unknown

29 (0.8 %)

16 (0.9 %)

9 (0.7 %)

4 (0.7 %)

0 (0.0 %)

0 (0.0 %)

  1. HER2 human epidermal growth factor receptor 2, FEC-DocG 5-fluorouracile, epirubicine, cyclophosphamide – docetaxel, gemcitabine, FEC-Doc 5-fluorouracile, epirubicine, cyclophosphamide – docetaxel, CT chemotherapy
  2. aAll tests without category “unknown”
  3. bKruskal-Wallis test
  4. cChi-square test
  5. dMantel-Haenszel linear-by-linear association chi-square test
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us